Follow
Joachim Aerts
Joachim Aerts
Unknown affiliation
Verified email at erasmusmc.nl
Title
Cited by
Cited by
Year
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ...
New England Journal of Medicine 373 (2), 123-135, 2015
87342015
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
24652017
Reduced lung-cancer mortality with volume CT screening in a randomized trial
HJ de Koning, CM van Der Aalst, PA de Jong, ET Scholten, K Nackaerts, ...
New England journal of medicine 382 (6), 503-513, 2020
22872020
Gene expression-based classification of non-small cell lung carcinomas and survival prediction
J Hou, J Aerts, B Den Hamer, W Van Ijcken, M Den Bakker, P Riegman, ...
PloS one 5 (4), e10312, 2010
7802010
Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non–small cell lung cancer: results of the …
WSME Theelen, HMU Peulen, F Lalezari, V van der Noort, JF De Vries, ...
JAMA oncology 5 (9), 1276-1282, 2019
7562019
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous …
F Barlesi, A Scherpereel, A Rittmeyer, A Pazzola, N Ferrer Tur, JH Kim, ...
Journal of Clinical Oncology 31 (24), 3004-3011, 2013
536*2013
Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer
M Reck, A Luft, A Szczesna, L Havel, SW Kim, W Akerley, MC Pietanza, ...
Journal of Clinical Oncology 34 (31), 3740-3748, 2016
5102016
PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced …
S Senan, A Brade, L Wang, J Vansteenkiste, S Dakhil, B Biesma, ...
Journal of clinical oncology 34 (9), 953-962, 2016
4722016
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled …
M Maio, A Scherpereel, L Calabrò, J Aerts, SC Perez, A Bearz, ...
The Lancet Oncology 18 (9), 1261-1273, 2017
4272017
Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021
SW Hanson, C Abbafati, JG Aerts, Z Al-Aly, C Ashbaugh, T Ballouz, ...
Jama 328 (16), 1604-1615, 2022
3952022
The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes
F Dammeijer, M van Gulijk, EE Mulder, M Lukkes, L Klaase, ...
Cancer cell 38 (5), 685-700. e8, 2020
3542020
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
WSME Theelen, D Chen, V Verma, BP Hobbs, HMU Peulen, JGJV Aerts, ...
The Lancet Respiratory Medicine 9 (5), 467-475, 2021
3432021
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial
S Uzun, RS Djamin, JAJW Kluytmans, PGH Mulder, NE van't Veer, ...
The Lancet Respiratory Medicine 2 (5), 361-368, 2014
3352014
Novel insights into mesothelioma biology and implications for therapy
TA Yap, JG Aerts, S Popat, DA Fennell
Nature Reviews Cancer 17 (8), 475-488, 2017
3242017
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
JD Veltman, MEH Lambers, M van Nimwegen, RW Hendriks, ...
BMC cancer 10, 1-13, 2010
3162010
Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial
N Horeweg, CM Van Der Aalst, E Thunnissen, K Nackaerts, C Weenink, ...
American journal of respiratory and critical care medicine 187 (8), 848-854, 2013
2832013
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the …
F Barlesi, A Scherpereel, V Gorbunova, R Gervais, A Vikström, C Chouaid, ...
Annals of oncology 25 (5), 1044-1052, 2014
2132014
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma
JP Hegmans, JD Veltman, ME Lambers, IJM de Vries, CG Figdor, ...
American journal of respiratory and critical care medicine 181 (12), 1383-1390, 2010
1872010
Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer
JG Aerts, JP Hegmans
Cancer research 73 (8), 2381-2388, 2013
1862013
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ...
Annals of Oncology 27 (3), 417-423, 2016
1592016
The system can't perform the operation now. Try again later.
Articles 1–20